S66.AU · Star Combo Pharma Limited

-

Please sign in to comment on S66.AU

1 Comment

Admin

4 years ago

Star Combo Pharma Limited is currently in a long term downtrend where the price is trading 15.7% below its 200 day moving average.

From a valuation standpoint, the stock is 85.3% cheaper than other stocks from the Consumer Defensive sector with a price to sales ratio of 1.0.

Star Combo Pharma Limited's total revenue sank by 30.3% to $15M since the same quarter in the previous year.

Its net income has increased by 143.0% to $530K since the same quarter in the previous year.

Finally, its free cash flow grew by 0.0% to $-2M since the same quarter in the previous year.

Based on the above factors, Star Combo Pharma Limited gets an overall score of 3/5.

CurrencyCode	AUD
Industry	Household & Personal Products
Exchange	AU
ISIN	AU0000004798
Sector	Consumer Defensive

Beta	0.52
Market Cap	16M
PE Ratio	11.5
Target Price	None
Dividend Yield	3.2%

ABOUT

Star Combo Pharma Limited

Star Combo Pharma Limited engages in the manufacturing and distribution of health food products and nutritional supplements in Australia and China. It operates in two segments, OEM Division and Austoyou Retail. The company develops, manufactures, markets, and sells natural health supplements and skin care products. It also provides its products through e-commerce platform to Chinese health product consumers. The company sells its products under the Costar, Living Healthy, Amax, and J&K brands. Star Combo Pharma Limited was founded in 2004 and is headquartered in Smithfield, Australia.

S66.AU · Star Combo Pharma Limited

-

Star Combo Pharma Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Star Combo Pharma Limited using a moving average strategy